 WOODCLIFF LAKE, N.J.--BUSINESS WIRE--Eagle Pharmaceuticals, Inc. Eagle or the Company NASDAQ: EGRX today announced that TREAKISYM ready-to-dilute RTD bendamustine hydrochloride 120 mgm2 liquid formulation has been approved for a new indication in combination with rituximab BR therapy as treatment for relapsed or refractory diffuse large B-cell lymphoma rr DLBCL by the Pharmaceuticals and Medical Devices Agency PMDA in Japan. This latest approval is another meaning 